Medical cannabis has been a hot topic in UK healthcare ever since the 2018 rescheduling opened doors to prescribing cannabis-based products for medicinal use. However, despite some progress, there remains confusion around what kind of clinical evidence the NHS accepts—particularly whether observational studies count when making prescribing decisions or updating guidelines.
In this article, we'll unpack the current NHS stance on medical cannabis evidence, explain the role of observational registries, explore the difference between legal prescribing and NHS funding, and highlight the practical realities faced by patients seeking these treatments in the UK.
What Changed in 2018: Rescheduling Medical Cannabis
Until November 2018, cannabis was classified under Schedule 1 drugs in the UK, meaning it was considered to have no medical value and high potential for misuse, and was therefore illegal to prescribe. The rescheduling of cannabis to Schedule 2 marked a watershed moment. This reclassification meant that cannabis-based products for medicinal use (CBPMs) became legally prescribable in very limited circumstances, given proper specialist oversight.
- Legal prescribing became possible: Specialist doctors on the General Medical Council (GMC) Specialist Register can now prescribe CBPMs under stringent criteria. Not automatically funded by the NHS: Legal prescribing does not equal NHS funding — most CBPM prescriptions are still private due to lack of routine NHS commissioning.
This distinction is vital: just because a product is legal and prescribable doesn’t mean the NHS will pay for it. Patients often find themselves caught in this gap, resorting to private clinics or paying out-of-pocket when their specialist recommends cannabis-based medicines.
Observational Registry Evidence: What Is It and Why Does It Matter?
In the debate over medical cannabis, observational studies and registries are often touted as crucial sources of insight because of the relative scarcity of large-scale randomised controlled trials (RCTs). Observational studies collect data on patients receiving treatment in routine practice without the strict controls of RCTs, offering insights into real-world effectiveness and safety.
Examples of such registries include those compiling patient outcomes for medical cannabis users over time, documenting symptom changes, side effects, and dosage patterns.
The key question is: Does the NHS accept or use this observational evidence when making decisions about cannabis prescribing?
NHS Approach to Clinical Evidence: Emphasis on RCTs
The NHS and its decision-making body, NICE (National Institute for Health and Care Excellence), traditionally prioritise randomised controlled trials (RCTs) as the gold standard for clinical evidence. NICE guidelines rely primarily on high-quality RCT data to issue recommendations, mainly because these trials minimise bias and provide the clearest picture of efficacy and safety.
Observational studies are considered important but usually play a complementary role, particularly when RCTs are unavailable or impractical. In the case of medical cannabis:
- The limited RCT data means NICE and NHS guidelines do not yet endorse cannabis-based products broadly. Observational registry data has contributed to increased understanding but is insufficient on its own to justify routine NHS funding or widespread prescribing guidance.
This cautious approach means the NHS remains hesitant to recommend cannabis widely without more robust evidence.
Specialist-Only Prescribing Rules for Medical Cannabis
Following 2018, NHS England set out strict prescribing rules:
- Only specialists on the GMC Specialist Register may prescribe CBPMs. Prescribers must have relevant expertise in the specific condition (e.g., neurology, pain medicine). Prescribing is generally a last resort after licensed treatments have been tried and failed.
This “specialist-only” approach is intended to drive cautious, evidence-based prescribing and aligns with NICE’s requirements for high-quality evidence before broader recommendation.
I'll be honest with you: patients interested in medical cannabis treatment can find clinics and specialist doctors via directories such as medicalcannabis.co.uk. However, these clinics often operate in the private sector due to specialist cannabis prescription uk the limited NHS funding.
Funding vs Legal Prescribing: The NHS Catch-22
It’s important to clarify the difference between being legally permitted to prescribe CBPMs and having those prescriptions funded through the NHS:
Aspect Description Legal Prescribing Allowed under law by specialist clinicians following 2018 rescheduling. NHS Funding Financial support from NHS for the medicine. Currently limited to very few exceptional cases.Most patients who get legal medical cannabis prescriptions pay privately due to NHS England not commissioning these products routinely. This means despite having a legitimate prescription, NHS patients often face significant cost barriers.
Unlicensed Cannabis-Based Medicines and the NHS
Many medical cannabis products used in the UK are unlicensed medicines. Unlike licensed drugs with full regulatory approval, unlicensed medicines:
- Have not undergone the complete MHRA licensing process. May have less robust evidence for safety and efficacy. Are frequently used when no licensed alternatives exist or licensed options have failed.
The NHS generally exercises caution with unlicensed medicines due to uncertainties around benefit, risk, and cost-effectiveness. This contributes to the hesitancy to fund CBPMs widely despite their legal prescribability. ...well, you know.
Some trusted sources, such as releaf.co.uk, provide straightforward explainer content clarifying the nuances of medical cannabis legality, prescribing rules, and NHS access.
Summary: What This Means for Patients
In a nutshell:
The NHS does not consider observational registry data on medical cannabis sufficient evidence to support routine prescribing or funding. Legal prescribing of cannabis-based products by specialists is allowed but tightly controlled and mostly limited to exceptional cases. Most cannabis-based medicines used are unlicensed, prompting NHS caution and contributing to lack of routine funding. Patients often find themselves accessing cannabis medicines privately, using specialist-only prescriptions where available. Resources like medicalcannabis.co.uk can help locate clinicians but do not guarantee NHS-funded access.Unfortunately, patients looking for medical cannabis via NHS routes need to understand this gap between legal prescribing and NHS acceptance of observational evidence or unlicensed cannabis-based medicines.
Looking Ahead: The Need for Better Evidence and Guidance
For the NHS to embrace medical cannabis more fully, clearer clinical evidence is paramount. Large-scale, high-quality RCTs addressing efficacy and safety in key conditions are needed to underpin NICE guidance updates and NHS commissioning decisions.
Meanwhile, observational registries can provide valuable supportive real-world data but remain insufficient on their own to change NHS policy.
If you’re considering medical cannabis and wondering about your options, reliable explainer sites like releaf.co.uk and clinic directories such as medicalcannabis.co.uk can be useful starting points. Just be aware that, for now, NHS prescribing guidance and funding remain conservative.
Price Transparency
Regarding cost, no specific NHS prices for cannabis-based products have been publicly stated in official guidance or recent NHS publications. Should prices be made available or quoted in future sources, it’s important to quote them exactly and attribute the source properly to avoid misinformation.
Final Thoughts
Yes, observational studies matter in understanding patient experiences with medical cannabis, but the NHS still prioritises RCTs and licensed medicines when making clinical and funding decisions. Until stronger evidence emerges, and NHS commissioning frameworks evolve, medical cannabis remains legal but largely a private treatment route in the UK.